NewsletterArchives

Click to subscribe, unsubscribe, change your email address or to change your delivery to a text only version.
Below displays the archive of our Brain Tumor Newsletter:
[ Oldest Issue | Previous Issue | Next Issue | Newest Issue ]
Having trouble viewing this email? View it in your browser.
Musella Foundation Logo and Name of Email Blast
Saturday, April 10, 2021
Issue 5813
Donations

Advocacy
Alert
The most important bill ever introduced into congress for brain tumor patients needs your support!
Click for details and to easily send letters.

Latest News

Discuss these articles in our forum!
  • ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma         This is good news for the Gliovac vaccine: the FDA said the phase 2 data (for recurrent glioblastoma) looks so good that the FDA wants the company to stop the phase 2 trial early and get started on the phase 3 trial with the assumption that if the phase 3 trial turns out good, the FDA will approve Gliovac. Howevr, I look at it differently. If the FDA says the phase 2 data is so good, and I know from previous reports that there were no significant side effects, why can't the FDA just stop the trial, and approve the vaccine so everyone can benefit.  The vaccine has doubled the median survival which is unheard of in brain tumor trials. Most of the other immunotherapies that are promising help a small % of the patients, so the median survival doesn't move.   This vaccine is available under the right to try program now.  For details go to http://erc-immunotherapy.com/ or contact me and we can help facilitate the process.


  • Immunotherapy combination shows early promise in aggressive brain cancers        Exciting report.  This combination of the drugs drugs atezolizumab and ipatasertib were tried on 10 glioblastoma patients. They report two patients did very well, and these patients had a PTEN mutation. Atezolizumab is a PDL1 inhibitor, and is easily available.  Ipatasertib is an experimental  small molecule inhibitor of AKT and hard to get.  I would like to see this tried in a larger trial.



Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details

To view past stories go to : https://virtualtrials.org/newsblast.cfm
To submit a story/press release go to: click here To unsubscribe, click here.
The article commentaries are the opinions of Al Musella, DPM and do not represent the official position of the Musella Foundation. Copyright 1992-2021 Musella Foundation - All rights reserved. No part of the Brain Tumor News Blast can be reproduced without the express written permission of the Musella Foundation.